FGFR3 and FGFR4 gene amplifications are rare, with frequencies of 0.31 and 0.16% across various tumors.26Currently, no approved drugs specifically target FGFR amplification, but clinical trials are underway for lung cancer, gastric cancer, and breast cancer, suggesting potential future treatment targets.27, 28, 29. This evidence concerns the gene FGFR3 and breast carcinoma.